BSE filing, NSE: KOVAI. Summary written from the filing by ALFA Finder's alert engine.
Kovai Medical Center and Hospital Ltd: key numbers
- Share price
- ₹5,898.95
- Market cap
- ₹6,455 Cr
- Revenue (annual)
- ₹1,586 Cr
- Net profit (annual)
- ₹244.5 Cr
- P/E (TTM)
- 25.6×Sector 51.1×
- Promoter holding
- 56.53%+0.01% QoQ
- FII holding
- 1.22%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kovai Medical Center and Hospital Ltd
All →Kovai Medical Center and Hospital Board Meeting Date
Kovai Medical Center intimated BSE that its Board will meet on 11 Nov 2026 to approve unaudited results for the quarter ended 30 Sep 2026. No financial figures or other decisions are disclosed yet.
Kovai Medical Center and Hospital Promoter Buying: ₹0.19 Cr
Promoter Pavai Property Developers acquired 316 shares of Kovai Medical Center via open market purchase for ₹0.19 Crore. This increases their holding slightly.
- Value
- ₹0.19 Cr
Kovai Medical Center and Hospital Promoter Buying: ₹0.31 Cr
Promoter entity Pavai Property Developers Private Limited purchased 500 equity shares of Kovai Medical Center & Hospital Ltd via market acquisition.
- Value
- ₹0.31 Cr
Kovai Medical Center and Hospital Annual General Meeting
Kovai Medical Center shareholders approved Dr. Arun N Palaniswami's re-designation as Joint Managing Director via postal ballot. The resolution passed with 96% assent in September 2026.
Kovai Medical Center and Hospital Annual General Meeting
Kovai Medical Center and Hospital Limited has issued a Postal Ballot Notice seeking shareholder approval for the re-designation of Dr. Arun N Palaniswami as Joint Managing Director.
Kovai Medical Center and Hospital Promoter Buying (Off-Market)
Promoter Palaniswami N acquired 12,59,725 shares (11.51% stake) of Kovai Medical Center via inheritance. His total holding increased from 0.09% to 11.60% post-transaction.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.